Vicki L. Sato - 18 Aug 2021 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role
Director
Signature
/s/ Tyler Nielsen, by power of attorney
Issuer symbol
DNLI
Transactions as of
18 Aug 2021
Net transactions value
-$86,139
Form type
4
Filing time
20 Aug 2021, 17:29:19 UTC
Previous filing
03 Aug 2021
Next filing
23 Aug 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Sale $41,316 -806 -0.61% $51.26 132,025 18 Aug 2021 Direct F1, F2, F3
transaction DNLI Common Stock Sale $44,823 -860 -0.65% $52.12 131,165 18 Aug 2021 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
F2 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $50.79 to $51.77 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3 Includes 2,074 restricted stock units.
F4 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $51.86 to $52.395 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.